AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AIM:AVCT) Poster presented at the AACR available to download
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell partners with Biocytogen and KNTSC
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
Avacta Group PLC (AVCT.L) Dose escalation in the phase I trial of AVA6000
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AVCT.L) Second pre|CISION Pro-drug Candidate Selected
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM
TPI provides its latest research note on Midatech Pharma plc (MTPH.L).
Midatech has announced an extension of the Q-Sphera R&D Collaboration (‘the Collaboration’) that was originally detailed on 21 July 2020, while also disclosing that the previously unnamed party is, in
Avacta Group PLC (AVCT.L) AffiDX Receives CE Mark for Consumer Self-Testing
AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Avacta Group PLC (AVCT.L) AffiDx® lateral flow test detects Omicron variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that
Avacta Group PLC (AVCT.L) FDA Approval of IND Application for AVA6000
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
